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A commentary on
Indoleamine 2,3-Dioxygenase-Expressing Aortic Plasmacytoid Dendritic Cells Protect against 
Atherosclerosis by Induction of Regulatory T Cells
by Yun TJ, Lee JS, Machmach K, Shim D, Choi J, Wi YJ, et al. Cell Metab (2016) 23(5):852–66. 
doi:10.1016/j.cmet.2016.04.010. Correction: Cell Metab (2016) 24(6):886. doi:10.1016/j.cmet. 
2016.11.008
Plasmacytoid dendritic cells (pDCs) are a unique subset of dendritic cells gaining increasing interest 
in atherosclerosis because of their ability to influence disease progression through a broad range 
of activities. Positioned at the border between innate and adaptive immunity, pDCs are found in 
lymphoid and somatic tissues, where they play different roles depending on anatomical location and 
context (1).
Several lines of evidence in recent years have highlighted the contribution of pDCs to the develop-
ment of atherosclerosis. Circulating pDCs are reduced in patients with coronary and peripheral 
artery diseases (1, 2); on the contrary, although scarce, pDCs become detectable in human athero-
sclerotic lesions, where their levels are either considered to be stable [based on blood dendritic cell 
antigen 2 (BDCA2) staining] or tend to increase (based on CD123 staining) with disease progression 
(1, 3–5). A recent study also suggested a causal association between pDC-derived type I IFN and the 
development of atherosclerosis in systemic lupus erythematosus (6).
Results from experimental animal studies were more conflicting; however, most of the data point 
toward a detrimental role played by pDCs in atherosclerosis. Initially, using an antibody-mediated 
depletion model, pDCs were shown to protect against atherosclerosis and vascular response to injury 
induced by bilateral placement of semiconstrictive collars in the carotid arteries of low-density 
lipoprotein receptor (Ldlr)−/− mice (3). However, subsequent studies demonstrated that antibody-
mediated depletion of pDCs inhibited experimental atherosclerosis in apolipoprotein-E (apoE)−/− 
mice (4, 7). More recently, by using a CD11c-restricted deletion of the transcription factor Tcf4/
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E2-2, which is required for pDC development and maintenance, 
pDC deficiency was shown to reduce plaque formation in Ldlr−/− 
chimeras (8). This phenotype was confirmed in chimeras lacking 
the pIII and IV promoters of MHC-II transactivator (CIITA) in 
pDCs, leading to MHC-II-restricted antigen presentation defects 
in pDCs. These data support a proatherogenic role for pDCs in 
experimental atherosclerosis and identify a critical role played by 
pDCs in sustaining atherogenic T cell response(s).
The proatherogenic role of pDCs has been challenged by the 
recent article published in Cell Metabolism (9), where the authors 
suggested that pDCs may exert a tolerogenic role in experimental 
atherosclerosis, being able to decrease plaque progression via 
induction of regulatory T cells (Tregs).
The authors performed a difficult and elegant work in the 
identification of a defined pure population of pDCs in the mouse 
aorta, being able to demonstrate for the first time, the capacity of 
aortic murine and human pDCs to produce type I IFN in both 
healthy and atherosclerotic vessels. The authors confirmed the 
scarce presence and anatomical location of pDCs in the intimal 
space and adventitia, as previously demonstrated (3, 7, 8); moreo-
ver, total aortic pDC numbers increased with atherosclerosis 
progression.
Importantly, the authors demonstrated that treatment with 
pDC-targeting Ab [plasmacytoid dendritic cell antigen-1 
(BST2/PDCA-1/CD317)], previously used to investigate pDCs 
in experimental atherosclerosis, was not fully selective, leading 
to partial (albeit not significant) aortic macrophage depletion. 
Previous immunofluorescence staining of aged apoE−/− mouse 
atherosclerotic arteries in our hands showed that a significant 
number of PDCA-1+ cells were present in the T cell area of arte-
rial tertiary lymphoid organs, with localization of PDCA-1 also 
observed in endothelial cells of high endothelial venules (10). Yun 
et al. (9) work complements our studies, directly demonstrating 
that antibody-mediated pDC depletion should be avoided in 
atherosclerosis research, given that PDCA-1 is promiscuously 
expressed in the vascular inflammatory environment.
The key experiments performed by the authors to assess pDC 
contribution to experimental atherosclerosis present incongru-
ences that merit discussion.
eFFICaCy oF pDC DePletIon 
aFter ProlonGeD treatment 
In BDCa2-DIPHtHerIa toXIn 
reCePtor (Dtr) mICe
To explore the role of pDCs in plaque formation, they generated 
atherosclerotic chimeric mice by reconstituting Ldlr−/− mice with 
bone marrow from BDCA2-DTR mice. These transgenic mice 
express a simian DTR under the transcriptional control of the 
human pDC gene promoter BDCA2 (11). In these animals, pDCs 
(SiglecH+B220+) are successfully and selectively depleted 24  h 
after diphtheria toxin (DT) treatment [administered intraperito-
neally (i.p.) at 100–120 ng/mouse] (11). In the original research 
article, DT-induced depletion persisted for 2–3 days (11). It was 
also suggested that pDCs could be depleted for longer periods 
with repeated DT administration, but no data were shown to 
support this statement. Several other studies have used BDCA2-
DTR mice; nevertheless, only one of those studies depleted pDCs 
for more than 2–3  weeks. In particular, pDCs were said to be 
depleted in BDCA2-DTR mice for 8  weeks in a lupus model; 
however, only splenic depletion data at 24 and 72 h were shown 
(12).
More recently, BDCA2-DTR mice have been crossed with 
apoE−/− mice to generate apoE−/− BDCA2-DTR mice for the 
investigation of pDCs in atherosclerosis (13). DT administration 
to induce pDC depletion for 4 weeks (0.01 mg/kg administered 
i.p. three times per week) during high-fat diet (HFD) did not 
affect lesion formation in the aortic sinus. Importantly, detailed 
analysis of depletion efficiency demonstrated complete pDC 
depletion for 1  week only. After 4  weeks of continuous DT 
administration, pDCs failed to express DTR anymore and, there-
fore, could not be depleted. On the contrary, the authors showed 
an increase in B cells in all organs, accompanied by changes in 
the inflammatory profile in pDC-“depleted” mice compared 
to controls. Although we cannot exclude that the breeding of 
BDCA2-DTR mice to apoE−/− may have contributed to altered 
pDC depletion, the available data highlight the importance to 
carefully evaluate depletion efficiency in long-term experiments 
with BDCA2-DTR mice.
Yun et  al. (9) used chimeric Ldlr−/−:BDCA2-DTR mice fed 
with HFD for 12 weeks, with or without DT treatment (0.5 μg/
mouse per week, i.p.), to deplete pDCs. Atherosclerotic plaque 
formation significantly increased in the sinus of pDC-depleted 
animals. Depletion efficiency was shown in BDCA2-DTR mice 
administered with DT twice at 24 h intervals. Similarly, selective 
depletion was shown in Ldlr−/−:BDCA2-DTR mice; however, 
the time point of assessment of aortic and spleen pDC depletion 
was not reported in the original manuscript. Subsequently, data 
showing partial pDC depletion in the spleen, after 12 weeks of 
DT injection, have been added as corrigendum to the original 
paper. However, pDCs were depleted in only 60% of the mice, 
and how long the depletion lasted after each DT injection was 
not shown. This is of particular relevance given that DT was only 
administered once per week. In addition, depletion efficacy in 
the aorta was not assessed at this later time point. As discussed 
above, it would have been fundamental to evaluate the efficacy 
and kinetics of pDC depletion in all target organs throughout 
the duration of the experiment. This represents a limitation of 
the study given that previous studies were unable to provide 
conclusive evidence of effective and continuous long-term pDC 
depletion in BDCA2-DTR mice.
Similarly, it would have been important to assess selectivity 
of the depletion in atherosclerotic mice following 12 weeks of 
HFD. pDCs are acutely and selectively depleted in BDCA2-DTR 
mice in both aorta and spleen in the steady state. However, on 
the one hand, TLR7/9 agonists have been shown to down-
regulate expression of BDCA2 in pDCs (14), suggesting that 
activated pDCs in advanced atherosclerotic vessels may be less 
susceptible to depletion; on the other hand, the truncated human 
BDCA2 promoter could give rise to off-target DTR expression, 
particularly in the advanced stages of atherosclerosis, where 
promiscuous expression of BDCA2 by other leukocyte subsets 
may occur.
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toXIC anD oFF-tarGet eFFeCtS oF Dt 
treatment
Importantly, controls for the DT treatment were not entirely ade-
quate. Eight weeks following chimera generation, Ldlr−/−:BDCA2-
DTR mice were fed with HFD and injected with PBS or DT for 
the subsequent 12  weeks. Treatments with mutant DT or 
DT-treated Ldlr−/−:WT-DTR- chimeric mice were not used as 
controls to assess any potential toxicity related to DT treatments, 
as conventionally performed (15, 16). Mice are generally resist-
ant to DT; however, several reports highlight potential DT toxic 
effects (17) and development of anti-DT antibodies (18). In addi-
tion, off-target effects have been observed following DT injection. 
For example, CD11c-DTR and CD11c-DOG mice developed 
neutrophilia 24 h after DT administration, which is independent 
from DC depletion (19). Moreover, ectopic DTR expression in 
DTR Tg mouse models may also lead to toxic effects of DT. For 
example, DT has been shown to be lethal in Zbtb46-DTR mice, 
due to aberrant expression of Zbtb46 in erythroid progenitors 
and endothelial cells (20).
In a similar experimental setting to Yun et al. (9), Biessen and 
coworkers observed no significant changes in lesion formation in 
Ldlr−/−:BDCA2-DTR mice fed with HFD and injected with DT or 
mutant DT (120 ng/mouse three times per week, i.p.) for 3 weeks 
(unpublished data). The experiment was terminated due to sig-
nificant decrease in body weight and granulocytosis observed in 
blood and spleen of DT-depleted mice at end point. These data 
confirm the importance to adequately control DT administration 
in experiments with DTR Tg mice.
merItS anD PItFallS oF tHe 
meCHanIStIC StUDIeS
Finally, the authors found that mouse and human aortic pDCs 
expressed the tolerogenic enzyme indoleamine 2,3-dioxygenase 
(IDO)-1, suggesting an activated/matured pDC phenotype. 
Furthermore, they propose a direct functional link between the 
presence of IDO-1+ pDCs and Treg generation in the diseased 
vessel. These data align with several earlier findings, including in 
the context of atherosclerosis, Daissormont et al. (3). However, 
both the latter study and that of Yun et al. (9) provided no dem-
onstration of a direct effect of pDCs or IDO expression by pDCs 
on vascular Tregs in vitro or in vivo. First, the authors showed an 
interesting correlation between aortic pDCs and Treg numbers 
with disease progression. Second, they demonstrated reduced 
Treg numbers in Ido1−/− mice compared to WT. However, in 
Ido1−/− mice, the knockout effect is not pDC restricted/specific 
and, therefore, we cannot rule out potential contributions from 
other leukocyte subsets known to express IDO, such as conven-
tional DCs, macrophages, and smooth muscle cells. Finally, the 
authors demonstrated that depletion of pDCs in atherosclerotic 
mice resulted in reduction of aortic Tregs. These findings are inter-
esting; however, implications are difficult to be interpreted given 
that no data on other T cell subsets were shown. Similarly, the 
authors demonstrated that antigen presentation by pDCs induced 
OVA-specific Tregs in the aorta of Ldlr−/−:OT-II chimeras. MHC 
class II-restricted antigen presentation by pDCs may lead to the 
expansion of all CD4+ Tg T cell subsets (that have not been inves-
tigated), and the effect may not, therefore, be restricted to Tregs.
leSSonS learneD anD ProPoSeD 
neXt StePS
The abovementioned limitations highlight the importance to 
deplete specifically and continuously pDCs in vivo. All the geneti-
cally modified mouse models developed to date present limita-
tions, and therefore, new selective, reproducible, and advanced 
tools are urgently required. pDCs may act in an immunogenic 
or tolerogenic manner in atherosclerosis depending on the 
specific anatomical niche, the local inflammatory environment, 
and the different stages of the pathology. Therefore, understand-
ing the delicate balance between pDC-driven immunogenic and 
tolerogenic response(s) is becoming increasingly crucial. At the 
same time, it would be key to understand the net contribution 
of vascular vs. systemic pDCs to disease development and 
progression and investigate why several leukocytes acquire 
a “pDC-like” phenotype in atherosclerotic arteries. As these 
studies progress, we will learn more about whether pDCs are 
indeed viable diagnostic, prognostic, and/or therapeutic targets 
in atherosclerosis.
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